Susquehanna International Group
SRPT icon

Susquehanna International Group’s Sarepta Therapeutics SRPT Stock Holding History

Susquehanna International Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.9M Buy
1,280,600
+103,800
+9% +$2.01M ﹤0.01% 1824
2025
Q4 		$25.3M Buy
1,176,800
+60,600
+5% +$1.28M ﹤0.01% 1966
2025
Q3 		$21.5M Buy
1,116,200
+532,100
+91% +$9.49M ﹤0.01% 2123
2025
Q2 		$9.99M Buy
584,100
+416,700
+249% +$17.8M ﹤0.01% 2830
2025
Q1 		$10.7M Sell
167,400
-213,800
-56% -$22.5M ﹤0.01% 2445
2024
Q4 		$46.4M Buy
381,200
+52,200
+16% +$6.4M 0.01% 1178
2024
Q3 		$41.1M Sell
329,000
-391,800
-54% -$54.2M 0.01% 1224
2024
Q2 		$114M Buy
720,800
+384,900
+115% +$49.4M 0.02% 541
2024
Q1 		$43.5M Sell
335,900
-413,900
-55% -$50.7M 0.01% 1125
2023
Q4 		$72.3M Sell
749,800
-21,300
-3% -$2.04M 0.01% 840
2023
Q3 		$93.5M Sell
771,100
-358,300
-32% -$40.5M 0.02% 648
2023
Q2 		$129M Buy
1,129,400
+437,800
+63% +$56.5M 0.03% 496
2023
Q1 		$95.3M Buy
691,600
+494,800
+251% +$64.2M 0.02% 608
2022
Q4 		$25.5M Buy
196,800
+112,200
+133% +$13M 0.01% 1324
2022
Q3 		$9.35M Buy
84,600
+23,300
+38% +$2.35M ﹤0.01% 2241
2022
Q2 		$4.59M Sell
61,300
-13,500
-18% -$993K ﹤0.01% 3322
2022
Q1 		$5.84M Sell
74,800
-269,900
-78% -$20.7M ﹤0.01% 3375
2021
Q4 		$31M Buy
344,700
+84,400
+32% +$7.22M ﹤0.01% 1437
2021
Q3 		$24.1M Sell
260,300
-53,200
-17% -$4.1M ﹤0.01% 1791
2021
Q2 		$24.4M Sell
313,500
-58,100
-16% -$4.4M ﹤0.01% 1817
2021
Q1 		$27.7M Sell
371,600
-228,300
-38% -$21.1M ﹤0.01% 1535
2020
Q4 		$102M Buy
599,900
+222,100
+59% +$32.9M 0.02% 650
2020
Q3 		$53.1M Buy
377,800
+3,100
+0.8% +$471K 0.01% 840
2020
Q2 		$60.1M Sell
374,700
-61,400
-14% -$8.36M 0.01% 729
2020
Q1 		$42.7M Sell
436,100
-433,800
-50% -$49.6M 0.01% 722
2019
Q4 		$112M Sell
869,900
-285,700
-25% -$28.8M 0.03% 441
2019
Q3 		$87M Sell
1,155,600
-104,300
-8% -$12.3M 0.03% 497
2019
Q2 		$191M Buy
1,259,900
+181,700
+17% +$22.1M 0.07% 229
2019
Q1 		$129M Buy
1,078,200
+428,100
+66% +$55M 0.05% 310
2018
Q4 		$70.9M Sell
650,100
-335,300
-34% -$41.9M 0.03% 476
2018
Q3 		$159M Sell
985,400
-158,100
-14% -$21.6M 0.05% 299
2018
Q2 		$151M Buy
1,143,500
+290,900
+34% +$27.4M 0.05% 299
2018
Q1 		$63.2M Sell
852,600
-1,675,400
-66% -$112M 0.02% 565
2017
Q4 		$141M Buy
2,528,000
+837,900
+50% +$44.4M 0.05% 317
2017
Q3 		$76.7M Buy
1,690,100
+460,600
+37% +$18.4M 0.03% 482
2017
Q2 		$41.4M Buy
1,229,500
+186,400
+18% +$6.07M 0.02% 703
2017
Q1 		$30.9M Sell
1,043,100
-513,800
-33% -$15.9M 0.02% 801
2016
Q4 		$42.7M Sell
1,556,900
-858,400
-36% -$34.5M 0.02% 623
2016
Q3 		$148M Sell
2,415,300
-193,000
-7% -$5.83M 0.07% 229
2016
Q2 		$49.7M Buy
2,608,300
+1,297,500
+99% +$24M 0.03% 517
2016
Q1 		$25.6M Buy
1,310,800
+6,500
+0.5% +$114K 0.01% 835
2015
Q4 		$50.3M Buy
1,304,300
+546,100
+72% +$17.7M 0.02% 601
2015
Q3 		$24.3M Buy
758,200
+124,700
+20% +$4.23M 0.01% 1052
2015
Q2 		$19.3M Buy
633,500
+202,000
+47% +$4.13M 0.01% 1337
2015
Q1 		$5.73M Sell
431,500
-303,100
-41% -$4.04M ﹤0.01% 2548
2014
Q4 		$10.6M Sell
734,600
-45,300
-6% -$767K ﹤0.01% 1972
2014
Q3 		$16.5M Buy
779,900
+109,100
+16% +$2.46M 0.01% 1605
2014
Q2 		$20M Sell
670,800
-806,600
-55% -$25.5M 0.01% 1408
2014
Q1 		$35.5M Buy
1,477,400
+353,900
+31% +$9.02M 0.02% 834
2013
Q4 		$22.9M Sell
1,123,500
-169,900
-13% -$5.05M 0.01% 1219
2013
Q3 		$61.1M Sell
1,293,400
-38,800
-3% -$1.49M 0.03% 503
2013
Q2 		$50.7M Buy
+1,332,200
New +$47.6M 0.03% 543

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's SRPT Position: Q1 2026 in Review

Susquehanna International Group increased its Sarepta Therapeutics (SRPT) stake by 110% in Q1 2026, buying an estimated $9.1M and bringing the position to 897,532 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Susquehanna International Group first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $124M in Q2 2018. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Susquehanna International Group held 897,532 shares of Sarepta Therapeutics worth $19.5M as of Q1 2026.
  • Susquehanna International Group bought 469,923 Sarepta Therapeutics shares in Q1 2026, an estimated $9.1M.
  • Sarepta Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2253 holding.
  • Susquehanna International Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Susquehanna International Group's Sarepta Therapeutics position peaked at $124M in Q2 2018.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.